SCHEMBL14364591

SCHEMBL14364591

CC(C)(C)c1ccc2[nH]c(-c3nonc3N)nc2c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.60
HPGD P15428 2/20 0.60
NPSR1 Q6W5P4 2/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
RPS6KA5 O75582 1/20 0.53
FGFR1 P11362 2/20 0.43
FLT3 P36888 2/20 0.43
CLK4 Q9HAZ1 2/20 0.43
PDPK1 O15530 2/20 0.43
PLK4 O00444 1/20 0.43
CHEK1 O14757 1/20 0.43
AURKA O14965 1/20 0.43
CHUK O15111 1/20 0.43
JAK2 O60674 1/20 0.43
ROCK2 O75116 1/20 0.43
MAP4K4 O95819 1/20 0.43
PAK4 O96013 1/20 0.43
CHEK2 O96017 1/20 0.43
ABL1 P00519 1/20 0.43
NTRK1 P04629 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14364618 0.87 ALDH1A1 (0.60) ALDH1A1HPGDNPSR1SMN1; SMN2RPS6KA5
SCHEMBL1902418 0.82 ALDH1A1 (0.65) ALDH1A1HPGDNPSR1SMN1; SMN2RPS6KA5
SCHEMBL1901797 0.82 ALDH1A1 (0.68) ALDH1A1HPGDNPSR1SMN1; SMN2RPS6KA5
SCHEMBL30612244 0.80 SMN1; SMN2 (0.65) ALDH1A1HPGDNPSR1SMN1; SMN2RPS6KA5
SCHEMBL26922233 0.80 SMN1; SMN2 (0.65) ALDH1A1HPGDNPSR1SMN1; SMN2RPS6KA5
SCHEMBL1901354 0.79 SMN1; SMN2 (0.60) ALDH1A1HPGDNPSR1SMN1; SMN2RPS6KA5
SCHEMBL28496270 0.76 FGFR1 (0.46) ALDH1A1HPGDNPSR1FGFR1FLT3
SCHEMBL30061285 0.76 FGFR1 (0.46) ALDH1A1HPGDNPSR1FGFR1FLT3
SCHEMBL14364577 0.76 HPGD (0.60) ALDH1A1HPGDNPSR1SMN1; SMN2RPS6KA5
SCHEMBL1160565 0.76 ALDH1A1 (1.00) ALDH1A1HPGDNPSR1SMN1; SMN2RPS6KA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2322521-B1 Heteroaryl compounds useful as inhibitors of GSK-3 VERTEX PHARMA (US) 2013-09-04 EP disclosed
US-20070270420-A1 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 VERTEX PHARMACEUTICALS INCORPORATED 2007-11-22 US disclosed
US-20070270420-A1 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 VERTEX PHARMACEUTICALS INCORPORATED 2007-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070270420-A1 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 GSK3B, GSK3A, GSKIP ALDH1A1 3514/4885HPGD 2444/4885NPSR1 4422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.